Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis

J Infect Dis. 2022 Nov 1;226(9):1588-1592. doi: 10.1093/infdis/jiac134.

Abstract

Breakthrough gastrointestinal COVID-19 was observed after experimental SARS-CoV-2 upper mucosal infection in a rhesus macaque undergoing low-dose monoclonal antibody prophylaxis. High levels of viral RNA were detected in intestinal sites contrasting with minimal viral replication in upper respiratory mucosa. Sequencing of virus recovered from tissue in 3 gastrointestinal sites and rectal swab revealed loss of furin cleavage site deletions present in the inoculating virus stock and 2 amino acid changes in spike that were detected in 2 colon sites but not elsewhere, suggesting compartmentalized replication and intestinal viral evolution. This suggests suboptimal antiviral therapies promote viral sequestration in these anatomies.

Keywords: SARS-CoV-2; breakthrough infection; gastrointestinal tract; nonhuman primates; suboptimal prophylaxis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • COVID-19*
  • Macaca mulatta
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus

Substances

  • Spike Glycoprotein, Coronavirus
  • Antibodies, Monoclonal
  • spike protein, SARS-CoV-2